Our results showing the efficacy of Merestinib 18 , 36 in suppressing not only MAPK-eIF4E signals but also CDK1 and the oncofetal RNA binding protein, IMP3, which is induced by MAPK signals and overexpressed linked to many types of aggressive tumors 37 are highly significant toward developing IBC-specific therapeutic strategies.
← all excerpts
Altered ribosomal profile in acquired resistance and reversal associates with pathological response to chemotherapy in inflammatory breast cancer.
1
—
—